Park-Ohio (NASDAQ:PKOH) & BioNexus Gene Lab (NASDAQ:BGLC) Critical Comparison

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and Park-Ohio (NASDAQ:PKOH – Get Free Report) are both small-cap industrials companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings for BioNexus Gene Lab and Park-Ohio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab 1 0 0 0 1.00
Park-Ohio 0 1 2 0 2.67

Park-Ohio has a consensus price target of $59.00, suggesting a potential upside of 40.44%. Given Park-Ohio’s stronger consensus rating and higher possible upside, analysts plainly believe Park-Ohio is more favorable than BioNexus Gene Lab.

Profitability

This table compares BioNexus Gene Lab and Park-Ohio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNexus Gene Lab -82.38% -32.92% -29.75%
Park-Ohio 2.04% 11.88% 3.18%

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 51.4% of Park-Ohio shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Comparatively, 31.1% of Park-Ohio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares BioNexus Gene Lab and Park-Ohio”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNexus Gene Lab $7.43 million 0.27 -$2.98 million ($1.26) -0.54
Park-Ohio $1.60 billion 0.38 $23.80 million $2.46 17.08

Park-Ohio has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Park-Ohio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioNexus Gene Lab has a beta of 4.28, meaning that its stock price is 328% more volatile than the S&P 500. Comparatively, Park-Ohio has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Summary

Park-Ohio beats BioNexus Gene Lab on 13 of the 14 factors compared between the two stocks.

About BioNexus Gene Lab

(Get Free Report)

BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making. The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications. BioNexus Gene Lab’s operations are primarily based in Malaysia.

About Park-Ohio

(Get Free Report)

Park-Ohio Holdings Corp. is a diversified industrial company that provides supply-chain management services and manufactures components and equipment for industrial and transportation markets. Its operations are organized around Supply Technologies, Assembly Components and Engineered Products. Through Supply Technologies, the company sources, manages and distributes production parts and supplies for customers. Its other businesses make products that include engineered components, forged and machined parts, industrial fasteners, and induction heating and melting equipment.

Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.